Quince Therapeutics(QNCX)
SOUTH SAN FRANCISCO, CA
Biotechnology1 H-1B visas (FY2023)Focus: Alzheimer's treatment
Quince Therapeutics is a life sciences company focused on Alzheimer's treatment.
Neurology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
International Ataxia Rating Scale in Younger Patients
Ataxia TelangiectasiaClinical Trials (1)
NCT01942850International Ataxia Rating Scale in Younger Patients
N/ADSP loaded RBC using EryDex System
HealthyClinical Trials (1)
NCT02380924Recovery and Survival of EryDex in Non-patient Volunteers
Phase 1EryDex
HealthyClinical Trials (1)
NCT01925859EryDex Pharmacokinetics in Healthy Volunteers
Phase 1Dexamethasone
Nervous System DisorderClinical Trials (1)
NCT01255358Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients
Phase 2Dex 21-P
Ulcerative ColitisClinical Trials (1)
NCT01171807Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis
Phase 2EryDex Low dose DSP
Nervous System DiseaseClinical Trials (1)
NCT02770807Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients
Phase 3Dexamethasone sodium phosphate
Ataxia TelangiectasiaClinical Trials (1)
NCT06664853Open-Label Extension of EryDex Study IEDAT-04-2022
Phase 3Dexamethasone
Crohn's DiseaseClinical Trials (1)
NCT01277289Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease
Phase 3EryDex System
Ataxia TelangiectasiaClinical Trials (1)
NCT03563053Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study
Phase 3Dexamethasone sodium phosphate
Ataxia TelangiectasiaClinical Trials (1)
NCT06193200Evaluate the Neurological Effects of EryDex on Subjects With A-T
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 10 clinical trials
H-1B (2023): 1 approval
SEC Filings: 2 available
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub